Study casts doubt on cost-effectiveness of dengue vaccine

Researchers cast doubt on the cost-effectiveness in some circumstances of screening people for prior dengue infection before immunizing them with Dengvaxia.
Dengvaxia (Sanofi Pasteur) is the first licensed vaccine against dengue, the mosquito-borne virus that causes approximately 9,000 deaths and an estimated 50 million to 100 million infections worldwide each year. Research has shown, however, that receiving the vaccine increases the risk for severe disease and hospitalization in patients with no prior exposure to the virus.
Based on these findings, WHO recommended that the vaccine be

Source link

Back to top button